Principal Investigator: Paul Rosenberg, M.D. [ Bio ]|
The goal of this study is to determine whether Methylphenidate is a more effective treatment for apathy in patients with mild to moderate Alzheimer’s disease than placebo. Participants are randomized to drug or placebo and followed for 7 weeks. Three sites in the U.S. are participating in the study. Approximately 20 patients will be enrolled at Johns Hopkins.
For more information, contact Lynn Smith at 410-550-9053.